BROOKS Stock View

Brooks Laboratories Ltd
stock-view-header

₹ 90.55

icon -0.03 | -0.03
Market Cap ₹( Cr.)
2,376.64
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
24-Sep-2023
 

The average score for Brooks Laboratories Ltd stands at 4 against 2, three months back.

Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company operates through the Pharmaceuticals segment. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. It offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The Company has manufacturing plants at Baddi, Himachal Pradesh. The Company manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
95.97
100 DMA(₹)
82.11
200 DMA(₹)
85.41
52 Weeks Range
56.50     124.73

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required